Perils and Pitfalls in the Interpretation of Clinical Trials: A Reflection on the Recent Experience in Multiple Sclerosis
- 18 February 1999
- journal article
- research article
- Published by S. Karger AG in Neuroepidemiology
- Vol. 18 (2) , 53-63
- https://doi.org/10.1159/000069408
Abstract
Therapeutic trials in multiple sclerosis, in part because of the marked intra- and inter-individual variability of its clinical course, are prone to serious flaws in both design and interpretation. As a consequence, it has been a common historical pattern that treatment regimens, which are enthusiastically recommended at one point in time, are later proven to be ineffective by more definitive studies. This review considers several recently published therapeutic trials in order to exemplify some of the difficulties that commonly arise in this area of clinical research.Keywords
This publication has 7 references indexed in Scilit:
- Single-leg strut fractures in explanted Björk-Shiley valvesThe Lancet, 1994
- The Effect of Corticosteroids for Acute Optic Neuritis on the Subsequent Development of Multiple SclerosisNew England Journal of Medicine, 1993
- Quality control functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT)Controlled Clinical Trials, 1993
- Design, methods, and conduct of the optic neuritis treatment trialControlled Clinical Trials, 1993
- One-sided or two-sided p values?Controlled Clinical Trials, 1988
- Some thoughts on two-tailed tests (and two-sided designs)Controlled Clinical Trials, 1988
- Some thoughts on one-tailed testsControlled Clinical Trials, 1988